A Phase 2a, Multicenter, Single Arm, Open- Label, Two-stage, Study To Evaluate The Efficacy, Safety, Tolerability And Pharmacokinetics Of Pf-06480605 In Subjects With Moderate To Severe Ulcerative Colitis
Phase of Trial: Phase II
Latest Information Update: 12 Apr 2018
At a glance
- Drugs PF 6480605 (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 05 Mar 2018 Planned End Date changed from 1 Sep 2018 to 30 Aug 2018.
- 05 Mar 2018 Planned primary completion date changed from 1 Jun 2018 to 14 Jun 2018.
- 20 Feb 2018 Status changed from active, no longer recruiting to recruiting.